The following table details the insider trading activities
(stock purchases, stock sales, and stock option exercises) of Borgeson Blake since 2021.
This trader's CIK number is 1856094.
At the time of last reporting, Borgeson Blake was the Director of Recursion Pharmaceuticals, Inc.. (stock ticker symbol RXRX).
Also see all insider trading activities at Recursion Pharmaceuticals, Inc..
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2024 | RXRX | 0 | $0 | 314,923 | $2,897,372 | 0 | $0 |
| 2023 | RXRX | 0 | $0 | 263,737 | $2,256,226 | 0 | $0 |
| 2022 | RXRX | 0 | $0 | 54,050 | $577,661 | 0 | $0 |
| 2021 | RXRX | 0 | $0 | 28,875 | $556,671 | 0 | $0 |
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2024-11-12 | RXRX | Sale | 11,447 | 7.64 | 87,455 |
| 2024-10-29 | RXRX | Sale | 11,447 | 6.72 | 76,923 |
| 2024-10-15 | RXRX | Sale | 11,447 | 6.67 | 76,328 |
| 2024-10-01 | RXRX | Sale | 11,447 | 6.22 | 71,154 |
| 2024-09-17 | RXRX | Sale | 11,447 | 6.84 | 78,331 |
| 2024-09-03 | RXRX | Sale | 11,447 | 6.26 | 71,715 |
| 2024-08-20 | RXRX | Sale | 11,447 | 7.12 | 81,536 |
| 2024-08-06 | RXRX | Sale | 11,447 | 6.82 | 78,079 |
| 2024-07-23 | RXRX | Sale | 11,447 | 8.48 | 97,036 |
| 2024-07-09 | RXRX | Sale | 11,447 | 7.32 | 83,734 |
| 2024-06-25 | RXRX | Sale | 11,447 | 9.51 | 108,803 |
| 2024-06-11 | RXRX | Sale | 11,447 | 8.45 | 96,761 |
| 2024-05-28 | RXRX | Sale | 11,447 | 9.17 | 104,946 |
| 2024-05-14 | RXRX | Sale | 20,054 | 10.12 | 202,926 |
| 2024-04-30 | RXRX | Sale | 11,447 | 7.95 | 90,969 |
| 2024-04-16 | RXRX | Sale | 11,447 | 7.66 | 87,729 |
| 2024-04-02 | RXRX | Sale | 11,447 | 8.82 | 100,939 |
| 2024-03-19 | RXRX | Sale | 20,054 | 10.79 | 216,422 |
| 2024-03-05 | RXRX | Sale | 20,054 | 12.06 | 241,811 |
| 2024-02-20 | RXRX | Sale | 20,054 | 12.68 | 254,224 |
| 2024-02-06 | RXRX | Sale | 11,447 | 9.30 | 106,491 |
| 2024-01-23 | RXRX | Sale | 20,054 | 10.58 | 212,091 |
| 2024-01-09 | RXRX | Sale | 20,054 | 13.51 | 270,969 |
| 2023-12-26 | RXRX | Sale | 20,054 | 10.63 | 213,153 |
| 2023-12-12 | RXRX | Sale | 11,447 | 7.40 | 84,696 |
| 2023-11-28 | RXRX | Sale | 11,447 | 6.72 | 76,923 |
| 2023-11-14 | RXRX | Sale | 8,885 | 6.32 | 56,153 |
| 2023-10-31 | RXRX | Sale | 8,885 | 5.28 | 46,868 |
| 2023-10-17 | RXRX | Sale | 8,885 | 6.58 | 58,481 |
| 2023-10-03 | RXRX | Sale | 8,885 | 7.29 | 64,780 |
| 2023-09-19 | RXRX | Sale | 8,885 | 8.36 | 74,278 |
| 2023-09-05 | RXRX | Sale | 8,885 | 8.79 | 78,134 |
| 2023-08-22 | RXRX | Sale | 8,885 | 8.91 | 79,183 |
| 2023-08-08 | RXRX | Sale | 17,770 | 11.39 | 202,329 |
| 2023-07-25 | RXRX | Sale | 18,719 | 14.61 | 273,465 |
| 2023-07-11 | RXRX | Sale | 8,885 | 6.89 | 61,190 |
| 2023-06-27 | RXRX | Sale | 8,885 | 7.39 | 65,642 |
| 2023-06-13 | RXRX | Sale | 15,485 | 9.98 | 154,509 |
| 2023-05-30 | RXRX | Sale | 8,885 | 8.79 | 78,134 |
| 2023-05-16 | RXRX | Sale | 8,885 | 5.09 | 45,242 |
| 2023-04-18 | RXRX | Sale | 8,885 | 5.93 | 52,732 |
| 2023-04-04 | RXRX | Sale | 8,885 | 6.53 | 57,992 |
| 2023-03-21 | RXRX | Sale | 8,885 | 7.40 | 65,740 |
| 2023-03-07 | RXRX | Sale | 8,885 | 8.33 | 73,985 |
| 2023-02-21 | RXRX | Sale | 8,885 | 7.73 | 68,707 |
| 2023-02-07 | RXRX | Sale | 8,885 | 8.81 | 78,259 |
| 2023-01-24 | RXRX | Sale | 8,885 | 8.71 | 77,370 |
| 2023-01-10 | RXRX | Sale | 8,885 | 7.68 | 68,281 |
| 2022-12-27 | RXRX | Sale | 8,885 | 7.25 | 64,371 |
| 2022-12-27 | RXRX | Sale | 8,885 | 7.25 | 64,371 |
| 2022-11-29 | RXRX | Sale | 8,885 | 8.76 | 77,788 |
| 2022-11-16 | RXRX | Sale | 17,770 | 11.12 | 197,602 |
| 2022-01-04 | RXRX | Sale | 9,625 | 18.03 | 173,529 |
| 2021-12-21 | RXRX | Sale | 9,625 | 18.75 | 180,478 |
| 2021-12-07 | RXRX | Sale | 9,625 | 20.40 | 196,321 |
| 2021-11-18 | RXRX | Sale | 9,625 | 18.69 | 179,872 |
Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Borgeson Blake (Director of Recursion Pharmaceuticals, Inc. at the time of this reporting) see the Securities and Exchange Commission (SEC) website.